Sarepta Therapeutics Stock
€10.15
Your prediction
Sarepta Therapeutics Stock
Pros and Cons of Sarepta Therapeutics in the next few years
Pros
Cons
Performance of Sarepta Therapeutics vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Sarepta Therapeutics | -6.990% | -16.220% | -32.084% | -92.540% | -91.201% | -87.661% | -92.555% |
Regeneron Pharmaceuticals Inc. | 0.500% | 2.828% | 7.480% | -51.061% | -29.051% | -16.437% | -8.276% |
Exact Sciences | 0.510% | -4.883% | -7.244% | -7.379% | -24.062% | -7.431% | -49.628% |
Incyte Corp. | 0.130% | 2.398% | 3.140% | -5.501% | -9.038% | -24.185% | -30.025% |

sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The financials of Sarepta Therapeutics, traded under the symbol AVII, reflect a complex picture shaped by its positioning in the Biotechnology and Medical Research sector. The company has been heavily investing in research and development, which is crucial in this industry. However, the resulting financial statements indicate significant losses, raising queries about its future performance and viability. While the potential for groundbreaking advancements in treatment options exists, investors must weigh the current financial challenges against future possibilities carefully.
Market Capitalization: With a market capitalization of approximately $12.9 billion, Sarepta has a robust presence in the biotech sector. This positioning facilitates investment opportunities and potential market confidence, reflecting the belief in its future innovations.
Revenue Growth: Revenues for Sarepta totaled about $1.4 billion in the most recent twelve months (TTM). This suggests that the company has viable product lines, delivering growth opportunities despite the ongoing losses.
Comments
News

Is This Stock a Buy After Soaring by 20% in 1 Day?
It's been a rough year for Sarepta Therapeutics (NASDAQ: SRPT), a small-cap biotech that develops medicines for rare diseases. The company's shares are down by 88% year to date due to safety issues

Sarepta Therapeutics Stock: FDA Action Triggers 90% Collapse
Sarepta Therapeutics shares have plummeted to just around $14, representing a catastrophic decline of over 90% in the past year. The devastating selloff follows the FDA's request for a voluntary

Sarepta Therapeutics Stock: Crisis Deepens After Third Death
Sarepta Therapeutics continues its downward spiral after a third patient death was reported in clinical trials, sending the stock plummeting to $18.21 - representing an 84.7% decline over the past